<?xml version="1.0" encoding="UTF-8"?>
<p>Camrelizumab is a humanized monoclonal antibody against programmed cell death 1 (PD-1) receptors. PD-1 receptors are expressed on the surface of T cells and act as negative regulators of T cell function. Camrelizumab has been reported to block PD-1′s binding to its ligand, PD-L1, thus inhibiting the immune escape of tumor cells [
 <xref rid="B76-pharmaceuticals-13-00096" ref-type="bibr">76</xref>]. Recently, in China, the drug has received conditional approval for the treatment of relapsed or refractory Hodgkin’s lymphoma. Camrelizumab is also being investigated as a possible therapy for other malignancies [
 <xref rid="B76-pharmaceuticals-13-00096" ref-type="bibr">76</xref>].
</p>
